Pulmonary Cell News 7.26 July 5, 2018 | |
| |
TOP STORYInvestigators showed that the natural product rocaglamide enhanced natural killer cell-mediated lysis of non-small cell lung cancer cells in vitro and tumor regression in vivo. [Autophagy] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists performed unbiased lipidomic analysis on human bronchial epithelial cells infected over a six hour period with the RV-A1b strain of rhinovirus to determine changes in 493 distinct lipid species. [J Lipid Res] Abstract | Full Article In alveolar epithelial cells, the autophagy marker LC3 and percent of cells containing LC3-positive autophagosome were significantly increased. [Cell Prolif] Abstract Inhaled TRIM72 Protein Protects Ventilation Injury to the Lung through Injury-Guided Cell Repair Investigators examined the mechanisms of exogenous TRIM72 protein (rhT72)-mediated lung cell protection in vitro and tested the efficacy of inhaled rhT72 in reducing tissue pathology in a mouse model of ventilator-induced lung injury. [Am J Respir Cell Mol Biol] Abstract The authors investigated the gene expression profiles of influenza A virus-infected versus mock-infected cells at the early stage of infection using a PCR array for death receptor pathway. [Physiol Genomics] Abstract LUNG CANCERResearchers found that growth differentiation factor 15 (GDF15) was downregulated in paired non-small-cell lung cancer (NSCLC) tissues and correlated with poor clinical outcomes in NSCLC. A functional experiment demonstrated that overexpression of GDF15 significantly repressed NSCLC proliferation both in vitro and in vivo. [Mol Ther Nucleic Acids] Full Article The authors investigated the molecular and cellular effects of exogenous hydrogen peroxide (H2O2) on Calu-6 and A549 lung cancer cells. Based on MTT assays, H2O2 inhibited the growth of Calu-6 and A549 cells with IC50 values of ~50 and 100 µM at 24 hours, respectively. [Oncol Rep] Abstract The transcript levels of cyclinD1 and GSK3β were significantly increased and the distal PAS usage of several oncogenes were decreased after cleavage factor Im 25 knockdown. [Biochem Biophys Res Commun] Abstract Scientists investigated the expression profile of long intergenic noncoding RNA, regulator of reprogramming (lincROR) in Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML-ALK) non-small-cell lung cancer tissues, and the potential role of lincROR in prognosis was then analyzed. [Onco Targets Ther] Full Article Subscribe to one of our other 19 science newsletters such as Intestinal Cell News & Human Immunology News. | |
| |
REVIEWSImmune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer The authors provide an overview of the emerging data on the role of programed cell death-1/programmed cell death ligand 1 and cytotoxic T lymphocyte-associated protein 4 inhibitors in the treatment of early-stage and locally advanced non-small cell lung cancer, with a focus on ongoing clinical trials and combination strategies. [Curr Treat Options Oncol] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSOSE Immunotherapeutics SA received approval from the Independent Data Monitoring Committee (IDMC) to continue Atalante 1, the company’s international pivotal Phase III clinical study of Tedopi® for the treatment of Non-Small Cell Lung Cancer (NSCLC) following immune checkpoint inhibitor treatment. [OSE Immunotherapeutics SA] Press Release Oncodesign Announces the Results of the Second Stage of Its Clinical Study in Lung Cancer Oncodesign announced the results of the second stage of its Phase I clinical study assessing the first radiotracer resulting from its Nanocyclix® technology. [Oncodesign] Press Release BioAtla, LLC announced the treatment of the first patient in its clinical trial BA3021-001 for BioAtla’s BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate. [BioAtla, LLC (PR Newswire Association LLC.)] Press Release Merck announced that the FDA has accepted for review a supplemental Biologics License Application for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as a first-line treatment for metastatic squamous non-small cell lung cancer, regardless of PD-L1 expression. [Merck & Co., Inc.] Press Release | |
| |
POLICY NEWSHidden Conflicts? Pharma Payments to FDA Advisers after Drug Approvals Spark Ethical Concerns In examining compensation records from drug companies to physicians who advised FDA on whether to approve 28 psychopharmacologic, arthritis, and cardiac or renal drugs between 2008 and 2014, Science found widespread after-the-fact payments or research support to panel members. The agency’s safeguards against potential conflicts of interest are not designed to prevent such future financial ties. [ScienceInsider] Editorial Hungarian Academy to Draw Up Alternative Research Budget The Hungarian Academy of Sciences is set to put forward an “alternative proposal” for the country’s research budget, after the government moved to put the Ministry of Innovation and Technology in charge of financing research institutions, seen as the latest attack on sector autonomy by the authoritarian Orbán administration. [Times Higher Education] Editorial University of Gothenburg Moves to Fire Professor for Misconduct The University of Gothenburg has taken steps to remove Suchitra Sumitran-Holgersson from her post as a professor there, after an investigation concluded that she manipulated images in seven out of ten papers. [The Scientist] Editorial Geneticist Francisco Ayala Quits after Sexual Harassment Accusations The University of California, Irvine, which found him guilty of inappropriate behavior, will remove Ayala’s name from buildings and scholarships. [The Scientist] Editorial
| |
EVENTSNEW 2018 National Cancer Research Institute (NCRI) Cancer Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Bioengineer – Infection and Immunity in Human Organoids (Charité) Research Technologist – Pulmonary (STEMCELL Technologies Inc.) Postdoctoral Associate – Chemotherapy and Radiation Therapy (Baylor College of Medicine) Postdoctoral Researcher – Lung Cancer (University of Oxford) Principal Investigators – Cancer (University of Alabama Birmingham) Postdoctoral Position – Immunology/Molecular Biology (National Heart, Lung and Blood Institute) Postdoctoral Position – Vascular or Lung Biology (Yale University School of Medicine) Postdoctoral Fellow – Human Lung Stem Cells and Regeneration (MedImmune) Postdoctoral Fellow – Virology and Respiratory Biology (MedImmune) Assistant or Associate Professor – Genetic Epidemiology (University of Kentucky) Postdoctoral Scholarship – Cancer Metabolism (Karolinska Institutet) Postdoctoral Fellow – Immunology (NYU Langone Health) PhD Student – Novel Concepts for Therapy of Allergy (Helmholtz Zentrum München) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|